Bayer earns FDA untitled letter for Nubeqa's 'attention-grabbing visuals'
30th April 2026 Uncategorised 0The FDA has reprimanded Bayer for the “attention-grabbing visuals” and “frequent scene changes” in ads for the company’s prostate cancer drug Nubeqa. More: Bayer earns FDA untitled letter for Nubeqa's 'attention-grabbing visuals' Source: fierce
read more